A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy (GO-VIVA)
A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
Sponsor: Janssen Research & Development, LLC
This PHASE3 trial investigates Arthritis, Juvenile and is currently completed. Janssen Research & Development, LLC leads this study, which shows 54 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
54 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Completed PHASE3
-
May 2025 — Jun 2025 [monthly]
Completed PHASE3
-
Mar 2025 — May 2025 [monthly]
Completed PHASE3
▶ Show 49 earlier versions
-
Feb 2025 — Mar 2025 [monthly]
Completed PHASE3
-
Jan 2025 — Feb 2025 [monthly]
Completed PHASE3
-
Nov 2024 — Jan 2025 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting PHASE3
-
Feb 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE3
-
Jan 2024 — Feb 2024 [monthly]
Active Not Recruiting PHASE3
-
Dec 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE3
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE3
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE3
-
Jun 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE3
-
May 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE3
-
Apr 2023 — May 2023 [monthly]
Active Not Recruiting PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Active Not Recruiting PHASE3
-
Jan 2023 — Feb 2023 [monthly]
Active Not Recruiting PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE3
-
Nov 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE3
-
May 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
-
Apr 2022 — May 2022 [monthly]
Active Not Recruiting PHASE3
-
Mar 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
-
Feb 2022 — Mar 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Active Not Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Feb 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE3
-
Aug 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE3
-
Dec 2018 — Aug 2019 [monthly]
Active Not Recruiting PHASE3
-
Sep 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Aug 2017 — Feb 2018 [monthly]
Recruiting PHASE3
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
Apr 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Dec 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Research & Development, LLC
For direct contact, visit the study record on ClinicalTrials.gov .